November 23, 2016 - By Marguerite Chambers · 0 Comments
The stock of Agenus Incorporated (NASDAQ:AGEN) registered an increase of 5.06% in short interest. AGEN’s total short interest was 8.09M shares in November as published by FINRA. Its up 5.06% from 7.70M shares, reported previously. With 1.51 million shares average volume, it will take short sellers 5 days to cover their AGEN’s short positions. The short interest to Agenus Incorporated’s float is 10.95%. About 511,296 shares traded hands. Agenus Inc (NASDAQ:AGEN) has risen 13.90% since April 21, 2016 and is uptrending. It has outperformed by 8.57% the S&P500.
Agenus Inc. is an immuno-oncology company. The company has a market cap of $390.95 million. The Firm is engaged in discovering and developing treatments for patients with cancer. It currently has negative earnings. The Company’s approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Insitutional Activity: The institutional sentiment increased to 1.93 in Q2 2016. Its up 1.13, from 0.8 in 2016Q1. The ratio increased, as 15 funds sold all Agenus Inc shares owned while 26 reduced positions. 7 funds bought stakes while 26 increased positions. They now own 34.68 million shares or 5.72% less from 36.79 million shares in 2016Q1.
Goldman Sachs Group Inc last reported 0% of its portfolio in the stock. Allianz Asset Mgmt Ag accumulated 123,875 shares or 0% of the stock. Blackrock Fund, a California-based fund reported 1.91 million shares. Valley Natl Advisers Incorporated, a Pennsylvania-based fund reported 3 shares. Pnc Group holds 0% or 11,397 shares in its portfolio. United Cap Fincl Advisers Lc last reported 0% of its portfolio in the stock. The Massachusetts-based Geode Cap Mngmt Ltd Limited Liability Company has invested 0% in Agenus Inc (NASDAQ:AGEN). Wells Fargo And Com Mn has 0% invested in the company for 407,048 shares. Tower Limited Com (Trc) has invested 0% of its portfolio in Agenus Inc (NASDAQ:AGEN). Citigroup Inc accumulated 0% or 16,651 shares. Moreover, Ingalls & Snyder Lc has 0.06% invested in Agenus Inc (NASDAQ:AGEN) for 252,300 shares. Guggenheim Limited Liability accumulated 0% or 20,164 shares. Fisher Asset Management Llc last reported 93,132 shares in the company. Blackrock Inv Mgmt Limited Company accumulated 288,041 shares or 0% of the stock. Alphamark Ltd has invested 0% of its portfolio in Agenus Inc (NASDAQ:AGEN).
Insider Transactions: Since September 6, 2016, the stock had 1 insider buy, and 0 sales for $188,700 net activity. The insider WIINBERG ULF bought 30,000 shares worth $188,700.
Out of 5 analysts covering Agenus (NASDAQ:AGEN), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Agenus has been the topic of 8 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Jefferies maintained the shares of AGEN in a report on Friday, July 29 with “Buy” rating. The rating was initiated by Jefferies with “Buy” on Wednesday, December 16. The stock of Agenus Inc (NASDAQ:AGEN) earned “Buy” rating by MLV on Monday, July 27. The rating was downgraded by Maxim Group on Tuesday, October 27 to “Hold”. As per Friday, March 11, the company rating was upgraded by Maxim Group. The rating was downgraded by H.C. Wainwright to “Neutral” on Friday, October 28. Maxim Group maintained the shares of AGEN in a report on Thursday, October 27 with “Buy” rating. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report.
Agenus Inc. (Agenus), incorporated on November 10, 1999, is an immuno-oncology company. The Firm is engaged in discovering and developing treatments for patients with cancer. The Company’s approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Firm has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP) vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development. The Firm has programs targeting GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1, CEACAM1 and other undisclosed targets.
More recent Agenus Inc (NASDAQ:AGEN) news were published by: Fool.com which released: “3 Red Flags on Agenus Inc’s Balance Sheet” on November 23, 2016. Also Fool.com published the news titled: “Why Fret Over Agenus Inc. Q3 Results?” on October 27, 2016. Prnewswire.com‘s news article titled: “Agenus to Present at the Jefferies 2016 London Healthcare Conference” with publication date: November 14, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marguerite Chambers